LARGE PARTICLE SIZE TALC FOR USE IN THE PLEURAL CAVITY

Indications
- chronic pleurisies, principally malignant
- spontaneous pneumothorax

Steritalc® is intended for medical use. According to the literature1), talc is more efficient than bleomycin and cyclines. It appears that talc is the best product for pleural symphysis available and can be used even if the application of other agents has failed.

Features
- Steritalc® is non-soluble and induces permanent pleurodesis. It is suitable for all pleurodesis indications.
- Steritalc® has similar side effects as cyclines (in particular: slight rise of body temperature). Any pain occurring can be reduced according to physician’s discretion, for example by using xylocaine 1% in the pleura or via the slurry. Compared with cyclines, Steritalc® is more effective and less painful.
- Steritalc® is guaranteed asbestos and latex free.
- Steritalc® has a perfectly controlled granulometry (large particle size) avoiding any migration as shown by Pr ASTOUL et al.2), Marseilles, France.
- Steritalc® is free of endotoxines.
- Steritalc® complies with the regulations of the European Pharmacopoeia (6th edition): Steritalc® is a pharmaceutical talc of a lamellar structure which is stable and physically, chemically and biologically inert. Steritalc® is mined at Luzenac, France.

The dose varies from 3 to 6g for malignant pleural effusion and generally does not exceed 2g for spontaneous pneumothorax. Individual doses according to physician’s discretion. Please follow instructions for use.

Steritalc® comes in three pharmaceutical forms allowing different ways of application:

- **Steritalc® Vial F2, F4**
  For physicians preferring to use talc in bulk, Steritalc® is available in vials, which can be used for slurry as well as for talc poudrage.

- **Steritalc® Spray**
  The spray is intended for talc poudrage. It contains 3g Steritalc® and comes with a 450 mm cannula.

- **Steritalc® PF3 Poudrage kit**
  Pulverisation is performed at room temperature. Therefore there is no risk of hypothermia or local necrosis.
  Each Steritalc® PF3 Poudrage kit comes with a 150 mm cannula which is supple and atraumatic, minimizing the risk of perforation of the pulmonary parenchyma. A longer cannula (450 mm length) is available as an accessory.
  The Steritalc® PF3 Poudrage kit is safe and easy to handle. Decanting is not necessary which saves time for the patient and the medical staff.

<table>
<thead>
<tr>
<th>REF</th>
<th>Steritalc® Description</th>
<th>Quantity of medical talc</th>
<th>Items/box</th>
</tr>
</thead>
<tbody>
<tr>
<td>16903</td>
<td>F2: Vial, 50 ml</td>
<td>2 g</td>
<td>4</td>
</tr>
<tr>
<td>16913</td>
<td>F4: Vial, 50 ml</td>
<td>4 g</td>
<td>4</td>
</tr>
<tr>
<td>16833</td>
<td>Spray, with cannula 450 mm</td>
<td>3 g</td>
<td>2</td>
</tr>
<tr>
<td>16863</td>
<td>PF3: Vial 30 ml, with balloon and cannula 150 mm (Poudrage Kit)</td>
<td>3 g</td>
<td>2 kits</td>
</tr>
<tr>
<td>16953</td>
<td>Accessory for 16863: Extra-long cannula 450 mm for Poudrage Kit PF3</td>
<td>3 g</td>
<td>10</td>
</tr>
<tr>
<td>16983</td>
<td>Accessory for 16863: Vial, 30 ml</td>
<td>3 g</td>
<td>4</td>
</tr>
</tbody>
</table>

1) Cf. reverse page for a bibliography.

2) Fraticelli, CHEST 2002; 122:1737-1741
Professional References


Cardillo G; Facciolo F; Carbone L; Regal M; Corzani F; Ricci A; Di Martino M; Martelli M; Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. European journal of cardio-thoracic surgery 21 (2002): 302-305

Erickson KV; Yost M; Bynoe R; Almond C; Nottingham J: Primary treatment of malignant pleural effusions: video-assisted thoracoscopic poudrage versus tube thoracostomy. The American surgeon 68 (2002): 955-959


Fraticelli A; Robagli-Schlupp A; Riera H; Monjanel-Mouterde S; Cau P; Astoul P: Distribution of calibrated talc after intrapleural administration: an experimental study in rats. Chest 122 (2002): 1737-1741

Mager HJ; Maesen B; Verzijlbergen F; Schramel F: Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung cancer 36 (2002): 77-81

Tschopp JM; Boutin C; Astoul P; Janssen JP; Grandin S; Bolliger CT; Delaunois L; Driesen P; Tassi G; Perruchoud AP: Talcage by medical Thoracoscopy for primary spontaneous pneumothorax is more cost-effective than drainage: a randomised study. European respiratory journal 20 (2002): 1003-1009

Antony VB; Loddenkemper R; Astoul P; Boutin C; Goldstraw P; Hott J; Rodriguez Panadero F; Sahn SA; Management of malignant pleural effusions. European respiratory journal 18 (2001): 402-419

Ferrer J; Villarino MA; Tura JM; Traveria A; Light RW: Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 119 (2001): 1901-1905

Milanez de Campos JR; Filho LO; de Campos Werebe E; Sette H Jr; Fernandez A; Filomeno LT; Jatene FB: Thoracoscopy talc poudrage, a 15 Year experience. Chest 119 (2001): 801-806


Tschopp JM; Bolliger CT; Boutin C: Treatment of spontaneous pneumothorax: why not simple talc pleurodesis by medical thoracoscopy. Respiration 67 (2000): 108-111

Marom EM; Patz EF Jr; Erasmus JJ; McAdams HP; Goodman PC; Herndon JD: Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis. Radiology 210 (1999): 277-281


